美罗培南治疗呼吸系统细菌性感染的随机对照临床研究  

A Randomized Controlled Clinical Study on Meropenem in Respiratory Bacterial Infections

作　　者：冯绍文[1] 何小敏[1] 许卫民[1] 吴喜英[1] 

机构地区：[1]中山大学附属第一医院药学部,广东广州510080

出　　处：《今日药学》2009年第11期42-45,共4页Pharmacy Today

摘　　要：目的评价美罗培南治疗呼吸系统细菌感染性疾病的疗效和安全性。方法采用随机对照临床试验方法，以头孢地秦作为对照。共入选有效病例232例，其中试验组118例，对照组114例。试验组予美罗培南静脉推注，每次500mg，每8h1次；对照组予头孢地秦静脉推注，每次2g，每12h1次，疗程均为7～14d。比较2组临床疗效及不良反应。结果试验组与对照组临床痊愈率分别为83．9％和79．8％，有效率分别为95．8％和95．6％，2组临床疗效比较无显著差异（P〉0．05）。细菌清除率均为99．2％，组间无显著差异（P〉0．05）。药物不良反应发生率分别为7．4％和6．8％，组间差异无显著意义（P〉0．05）。结论美罗培南治疗临床呼吸系统常见急性细菌感染性疾病与头孢地秦一样有效、安全。Objective To evaluate the efficacy and safety of tions. Methods A single blind randomized, parallel controlled meropenem in the treatment of respiratory bacterial infecclinical trial was carried out. In the study, 118 patients were enrolled in treatment group （ meropenem 500 mg IV. q8 h） , and another 114 patients were enrolled in control group （ cefdizime 2 g IV. q12 h）, with a course of 7 to 14 d for both groups. The clinical efficacy and safety together with adverse reactions were investigated and compared between 2 groups. Results The cure rates and total effective rates for the treatment and control groups were 83.9% , 79.8% , 95.8% , and 95.6% , respectively. The bacterial clearance rates were both 99.2%, and the incidences of drug adverse reactions were 7.4% and 6.8%, respectively. There were no sta- tistically significant differences between the results of both groups （ P 〉 0.05 ）. Conclusion Meropenem is effective and safe for treating acute bacterial infection.

关 键 词：细菌性感染 随即对照试验 美罗培南 头孢地秦 

分 类 号：R978[医药卫生—药品]